43.45

2.05% -0.91

After Hours: 43.90 0.45 +1.04%

Vera Therapeutics Inc (VERA)

Overview News Price History Option Chain Financials Discussions Forecast

Vera Therapeutics Inc stock is traded at $43.45, with a volume of 1.32M. It is down -2.05% in the last 24 hours and up +8.73% over the past month. Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Previous Close:

$44.36

Open:

$44.41

24h Volume:

1.32M

Relative Volume:

1.13

Market Cap:

$3.12B

Revenue:

Net Income/Loss:

$-299.62M

P/E Ratio:

-9.3162

EPS:

-4.6639

Net Cash Flow:

$-241.73M

1W Performance:

+7.74%

1M Performance:

+8.73%

6M Performance:

+40.16%

1Y Performance:

+101.25%

1-Day Range:

$42.49

$44.55

1-Week Range:

$39.57

$47.00

52-Week Range:

$18.76

$56.05

Vera Therapeutics Inc Stock (VERA) Company Profile

Name

Vera Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

650-770-0077

Address

2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE

Employee

249

Twitter

Next Earnings Date

2024-08-08

Latest SEC Filings

VERA's Discussions on Twitter

Compare VERA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VERA Vera Therapeutics Inc	43.45	3.18B	0	-299.62M	-241.73M	-4.6639
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-11-26	Upgrade	Wolfe Research	Peer Perform → Outperform
Oct-16-25	Initiated	BofA Securities	Buy
Aug-04-25	Downgrade	Wolfe Research	Outperform → Peer Perform
May-05-25	Resumed	H.C. Wainwright	Buy
Feb-04-25	Initiated	Wolfe Research	Outperform
Jan-28-25	Initiated	Goldman	Buy
Nov-21-24	Initiated	Wells Fargo	Overweight
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jan-25-24	Initiated	Oppenheimer	Outperform
Jan-08-24	Initiated	Cantor Fitzgerald	Overweight
Dec-18-23	Initiated	Raymond James	Outperform
Nov-10-23	Upgrade	Jefferies	Hold → Buy
Aug-16-23	Initiated	Guggenheim	Buy
Jan-04-23	Downgrade	Jefferies	Buy → Hold
Jan-04-23	Downgrade	Wedbush	Outperform → Neutral
Jul-12-22	Initiated	JP Morgan	Overweight
May-02-22	Initiated	H.C. Wainwright	Buy
Apr-19-22	Initiated	Wedbush	Outperform

View All

Vera Therapeutics Inc Stock (VERA) Latest News

05:41 AM

VERA (NASDAQ: VERA) director sells 16,925 shares for $710,577.51 — Form 144 - Stock Titan

Apr 14, 2026

Apr 13, 2026

Panic Selling: Is Vera Therapeutics Inc vulnerable to short sellersQuarterly Risk Review & Verified Short-Term Trading Plans - baoquankhu1.vn

Apr 13, 2026

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com

Apr 13, 2026

Discipline and Rules-Based Execution in VERA Response - Stock Traders Daily

Apr 13, 2026

Vera Therapeutics Announces Inducement Grants - National Today

Apr 13, 2026

Apr 12, 2026

Vera Therapeutics (VERA) Valuation Check After Recent Share Price Rebound - Sahm

Apr 12, 2026

Apr 11, 2026

Risk Check: Does Vera Therapeutics Inc align with a passive investing strategyTrade Entry Report & Community Consensus Stock Picks - baoquankhu1.vn

Apr 11, 2026

Vera Therapeutics stock rises after crossing above key SMA - Intellectia AI

Apr 11, 2026

Published on: 2026-04-11 13:37:36 - baoquankhu1.vn

Apr 11, 2026

Apr 10, 2026

Can Vera Therapeutics Inc deliver consistent EPS growth2026 Bull vs Bear & High Yield Stock Recommendations - baoquankhu1.vn

Apr 10, 2026

Vera Therapeutics Grants Inducement Awards to New Employees Under 2024 Inducement Plan - Quiver Quantitative

Apr 10, 2026

Vera Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Apr 10, 2026

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets

Apr 10, 2026

Vera Therapeutics issues stock awards to 89 new employees - Stock Titan

Apr 10, 2026

Is Vera Therapeutics (VERA) Still Attractive After An 87% One Year Share Price Surge - Yahoo Finance

Apr 10, 2026

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget

Apr 10, 2026

Apr 09, 2026

Board of Vera Therapeutics (VERA) seeks votes on directors, auditor and say-on-pay - Stock Titan

Apr 09, 2026

Is It Too Late To Consider Vera Therapeutics (VERA) After Its Recent Share Price Surge? - Sahm

Apr 09, 2026

Apr 06, 2026

Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight - GlobeNewswire Inc.

Apr 06, 2026

Apr 03, 2026

BofA Initiates Coverage of Vera Therapeutics (VERA) With a Buy Rating - MSN

Apr 03, 2026

Apr 02, 2026